Trispecific Antibody
May 13, 2024
Bispecific and Trispecific Antibodies: Are They Better Than CAR-Ts?
CAR-T therapy has been given the green light for treating blood cancers, but it hasn’t demonstrated sustained effectiveness against solid tumors thus far. The focus of ongoing CAR-T development leans heavily toward blood cancers rather than solid ones. On the other hand, bispecific antibodies have gained approval f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
